HPTN 091 Study Shows Encouraging Uptake and Adherence to Oral PrEP Among Transgender Women October 10, 2024
Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women—Findings from HPTN 084 Study July 28, 2022
HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention December 21, 2021
Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains January 26, 2021
HPTN Awarded U.S. National Institutes of Health Funding to Continue Research Agenda November 30, 2020
HPTN 084 Study Demonstrates Superiority of CAB LA to Oral TDF/FTC for the Prevention of HIV November 09, 2020
Long-acting injectable cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men May 18, 2020